Short-Term Efficacy and Safety of Blinatumomab in Early Postinduction Intensification Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Blinatumoab公司 医学 不良事件通用术语标准 内科学 不利影响 挽救疗法 急性淋巴细胞白血病 微小残留病 化疗 儿科 肿瘤科 白血病 淋巴细胞白血病
作者
Yanming Li,Peijing Qi,Ying Wu,Jiaole Yu,Yuanyuan Zhang,Huiqing Liu,Bei Hou,Jie Yang,Huyong Zheng,Tianyou Wang,Ruidong Zhang
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 5901-5901
标识
DOI:10.1182/blood-2023-188669
摘要

Background: Multidrug chemotherapy is the main treatment for children with B-cell acute lymphoblastic leukemia (B-ALL), which has been associated with multiple long-term complications and high rates of treatment non-completion due to toxicities. Recently, blinatumomab has proven to be effective and well-tolerated in the treatment of relapsed or refractory pediatric B-ALL. However, there is still a lack of reports about the real-world application of blinatumomab in pediatric B-ALL who achieved first complete remission (CR). O bjectives: To assess the short-term efficacy and safety of blinatumomab in early postinduction intensification therapy for children with B-ALL who had achieved first complete remission in a real-world setting. M ethods: A single-center retrospective analysis was performed to collect data on pediatric B-ALL patients (pts) who received blinatumomab monotherapy during early postinduction intensification therapy. All pts had undergone China Children's Leukemia Group (CCLG)-2018 induction chemotherapy until achieving CR. Blinatumomab treatment was initiated after obtaining consent from patients and caregivers, following detailed counseling about the potential risks and benefits. Efficacy was assessed based on minimal residual disease (MRD) negativity (<0.01%) using multiparameter flow cytometry (MFC). Adverse events (AEs) were assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. R esult: From September 2022 to July 2023, A total of 11 pts were included in this study due to chemotherapy intolerance: median age was 3 years (range, 1 to 11 years) with 54.5% (n=6) being male. Before blinatumomab therapy, MRD was detected in four pts with values of 0.024%, 0.037%, 10%, and 0.09%, respectively.The remaining pts tested negative for MRD. After one cycle of blinatumomab therapy, all MRDpos pts showed a decline in MRD, and 75% achieved undetectable MRD. The median follow-up time was 3 months. A total of 28 AEs were reported, with 75% classified as grade 1-2 and the remaining 25% as grade 3-4. The most frequently reported AEs were grade 1-2 fever (90.9%), observed within 7 days of treatment. Grade 3-4 hematological AEs included decreased white blood cell count and decreased neutrophil count. Additionally, four cases of infection, two cases of transient rash and one case of grade 2 diarrhea were observed. No pts experienced immune effector cell-associated neurotoxicity syndrome (ICANS), grade 3-4 cytokine release syndrome (CRS) or unexpected serious adverse events (SAEs). Furthermore, none of the AEs resulted in treatment delay, dose reduction or discontinuation. All pts experiencing treatment-associated toxicities recovered and proceeded to consolidation therapy. C onclusion: The use of blinatumomab in early intensification demonstrated promising short-term efficacy and a manageable safety profile in pediatric B-ALL pts. However, further confirmation of these results requires larger, randomized clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wqhao完成签到,获得积分10
刚刚
Maestro_S的应助被郭永强采纳,获得10
刚刚
1秒前
1秒前
萍萍完成签到,获得积分10
1秒前
菜黎明发布了新的文献求助10
1秒前
科研通AI6.2的应助被孤独梦曼采纳,获得10
2秒前
默默寒天完成签到,获得积分10
2秒前
2秒前
余香的应助被小郑爱学习采纳,获得10
3秒前
xing525888完成签到,获得积分10
3秒前
4秒前
香蕉觅云的应助被阿泽采纳,获得10
4秒前
所所的应助被超幸运的Stary采纳,获得10
4秒前
WWWUBING完成签到,获得积分10
4秒前
5秒前
CHEN发布了新的文献求助10
5秒前
局外人发布了新的文献求助10
5秒前
maxiaole的应助被loii采纳,获得10
5秒前
6秒前
传奇3的应助被哦莫采纳,获得10
6秒前
墨白cai发布了新的文献求助10
6秒前
陈蔡宇完成签到,获得积分10
7秒前
慕青的应助被仁爱灵安采纳,获得10
7秒前
隐形太英发布了新的文献求助20
7秒前
兮兮完成签到,获得积分10
8秒前
xianqing完成签到,获得积分10
8秒前
张醒醒完成签到,获得积分10
8秒前
YiiOuO完成签到 ,获得积分10
8秒前
成就紫真发布了新的文献求助10
8秒前
111完成签到,获得积分10
9秒前
Leo完成签到,获得积分10
9秒前
three发布了新的文献求助10
9秒前
9秒前
Winfrednano完成签到,获得积分10
10秒前
10秒前
sym完成签到,获得积分20
10秒前
隐形曼青的应助被wxl采纳,获得10
10秒前
小石头发布了新的文献求助10
11秒前
美年达完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817